AIM ImmunoTech (NYSEAMERICAN:AIM) Issues Earnings Results

AIM ImmunoTech (NYSEAMERICAN:AIM – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.43) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.03 million during the quarter.

AIM ImmunoTech Stock Performance

AIM opened at $0.29 on Friday. AIM ImmunoTech has a 1-year low of $0.21 and a 1-year high of $2.98. The stock has a market cap of $4.16 million, a P/E ratio of -0.09 and a beta of 1.20. The stock’s 50 day simple moving average is $0.35 and its 200 day simple moving average is $0.60. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01.

Get AIM ImmunoTech alerts:

Institutional Trading of AIM ImmunoTech

A hedge fund recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new position in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 1.31% of AIM ImmunoTech as of its most recent SEC filing. Institutional investors and hedge funds own 12.02% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets cut their price target on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $9.00.

View Our Latest Report on AIM

About AIM ImmunoTech

(Get Free Report)

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.

Featured Stories

• Five stocks we like better than AIM ImmunoTech
• 3 Stocks Whose Charts May Be Signaling the Next Big Move
• Quantum Earnings Week: Winners and Losers Are Finally Emerging
• Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
• Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.